An article published in Nature Communications on the pilot study carried out in Catalonia to evaluate the self-collection of biological samples reveals the high acceptability of the proposal and the key role of diagnosis in people without symptoms of mpox.
At the IGTP TODAY
A study has identified a molecule that could potentially be a target for the development of immunotherapies, led by IrsiCaixa AIDS Research Institute and spearheaded by Julia García-Prado, principal investigator at the same centre and scientific director of the Germans Trias i Pujol Research Institute (IGTP).
The collaborative project InMaM, part of the Complementary Plan for Biotechnology Applied to Health, involving both Catalonia and the Basque Country, aims to discover new immunotherapy-based treatments for metastatic breast cancer.
A study co-led by researchers from IGTP, IIB Sant Pau and IDIBGI concludes that direct transport to a referral centre for endovascular treatment may not be the best option for patients with a final diagnosis of intracerebral haemorrhage or haemorrhagic stroke.
A study published in Nature unveils new genetic insights into COVID-19 susceptibility and severity. This work marks a significant advancement in our understanding of the role genetics play in determining COVID-19 outcomes.
RIGHT PLUS network formalised in Buenos Aires as a collaboration between academic centres and civil society in Ibero-America
The Ibero-American network RIGHT PLUS, of which the CEEISCAT is a founding member and, together with Coalition Plus, co-coordinator, has presented its launch at a meeting in Buenos Aires (Argentina) on 28-29 August.
The CEEISCAT collaborates with UNAIDS and the Ministry of Public Health of the Dominican Republic to improve retention in antiretroviral treatments for HIV
Dr Jordi Casabona spent a week on the island working directly with international organizations, ministries, hospitals, and civil society.
A new lung cancer treatment has allowed 36.8% of patients to achieve complete tumour disappearance, compared to the 6.9% rate of the standard post-surgery treatment. In addition, 85% of patients survive two years after receiving chemo-immunotherapy before surgery compared to 63% who receive chemotherapy alone before surgery. The study involved oncologist from ICO Badalona and IGTP researcher, Teresa Morán.
Recruitment for the clinical trial TÉSTATE PrEP has started. This clinical trial has been designed by the Centre for Epidemiological Studies on HIV/AIDS in Catalonia (CEEISCAT) to implement a pilot plan for online HIV/STI screening in PrEP users.
One of the most commonly practised cardiovascular health interventions, the coronary bypass, could undergo a revolutionary innovation with the joint research carried out by the Blood and Tissue Bank (BST), the Germans Trias i Pujol Research Institute (IGTP) and the Vascular Engineering and Applied Biomedicine Group (GEAB) of the IQS (URL). The three centres are working to develop a vascular graft from donor veins that can be used for bypass surgery to restore blood flow.